Table 3.
Main studies reporting anakinra administration in pediatric Behçet disease.
Type of study | Patients (n) | Dose | Response | Adverse events | Follow up (months) | |
---|---|---|---|---|---|---|
Bilgner et al.41 | Case report | 1 (also affected by FMF) | 1 mg/kg/day | Remission | NA | 18 |
Urgulu et al.42 | Letter to the editor | 1 | 2 mg/kg/day | Persistent uveitis | NA | 1 |
Cantarini et al.40 | Case series | 1 | 2 mg/kg/day and after 4 months 2.5 mg/kg/day for a relapse | Partial response | NA | 9 |
FMF, familial Mediterranean fever; NA, not available.